“I worked with Aaron for several years in the lab. Aaron’s inquisitive nature and can-do attitude was the perfect combination to attack novel scientific concepts at the bench and effectively drive projects through the development pipeline. His ability to communicate these scientific ideas alongside his innate organizational abilities made us a highly effective, scientific working partnership. Aaron would be a valuable contributor to any team, and I really hope we get to work together again in the future.”
About
As the Co-Founder and CEO of KiraGen Bio, I'm proud to lead a team of innovators…
Activity
-
✨ The HBS adventure has come to a close. Thank you to my amazing family, partner and friends for making it possible! I am thrilled to announce that…
✨ The HBS adventure has come to a close. Thank you to my amazing family, partner and friends for making it possible! I am thrilled to announce that…
Liked by Aaron Edwards
-
The megaTAL platform takes flight! Excited to join Novo Nordisk and continue the development of an in vivo gene editing therapy for Hemophilia. Even…
The megaTAL platform takes flight! Excited to join Novo Nordisk and continue the development of an in vivo gene editing therapy for Hemophilia. Even…
Liked by Aaron Edwards
Experience
Education
Publications
-
Cytosine Base Editing Enables Quadruple-Edited Allogeneic CAR-T Cells for T-ALL
Blood
Allogeneic chimeric antigen receptor T cell (CART) therapies require multiple gene edits to be clinically tractable. Most allogeneic CART have been created using gene editing techniques that induce DNA double-stranded breaks (DSBs), resulting in unintended on-target editing outcomes with potentially unforeseen consequences. Cytosine base editors (CBEs) install C•G to T•A point mutations in T cells with between 90-99% efficiency to silence gene expression without creating DSBs, greatly reducing…
Allogeneic chimeric antigen receptor T cell (CART) therapies require multiple gene edits to be clinically tractable. Most allogeneic CART have been created using gene editing techniques that induce DNA double-stranded breaks (DSBs), resulting in unintended on-target editing outcomes with potentially unforeseen consequences. Cytosine base editors (CBEs) install C•G to T•A point mutations in T cells with between 90-99% efficiency to silence gene expression without creating DSBs, greatly reducing or eliminating undesired editing outcomes following multiplexed editing as compared to CRISPR-Cas9. Using CBE, we developed 7CAR8, a CD7-directed allogeneic CART created using four simultaneous base edits. We show that CBE, unlike CRISPR-Cas9, does not impact T-cell proliferation, lead to aberrant DNA damage response pathway activation or result in karyotypic abnormalities following multiplexed editing. We demonstrate 7CAR8 to be highly efficacious against T-cell acute lymphoblastic leukemia (T-ALL) using multiple in vitro and in vivo models. Thus, CBE is a promising technology for applications requiring multiplexed gene editing and can be used to manufacture quadruple-edited 7CAR8 cells with high potential for clinical translation for relapsed and refractory T-ALL.
-
Highly efficient multiplexed base editing enables the development of universal CD7-targeting CAR-T cells to treat T-ALL
Society for Immunotherapy of Cancer
Presentation at SITC
-
Directed evolution of adenine base editors with increased activity and therapeutic application
Nature Biotechnology
The foundational adenine base editors (for example, ABE7.10) enable programmable A•T to G•C point mutations but editing efficiencies can be low at challenging loci in primary human cells. Here we further evolve ABE7.10 using a library of adenosine deaminase variants to create ABE8s. At NGG protospacer adjacent motif (PAM) sites, ABE8s result in ~1.5× higher editing at protospacer positions A5–A7 and ~3.2× higher editing at positions A3–A4 and A8–A10 compared with ABE7.10. Non-NGG PAM variants…
The foundational adenine base editors (for example, ABE7.10) enable programmable A•T to G•C point mutations but editing efficiencies can be low at challenging loci in primary human cells. Here we further evolve ABE7.10 using a library of adenosine deaminase variants to create ABE8s. At NGG protospacer adjacent motif (PAM) sites, ABE8s result in ~1.5× higher editing at protospacer positions A5–A7 and ~3.2× higher editing at positions A3–A4 and A8–A10 compared with ABE7.10. Non-NGG PAM variants have a ~4.2-fold overall higher on-target editing efficiency than ABE7.10. In human CD34+ cells, ABE8 can recreate a natural allele at the promoter of the γ-globin genes HBG1 and HBG2 with up to 60% efficiency, causing persistence of fetal hemoglobin. In primary human T cells, ABE8s achieve 98–99% target modification, which is maintained when multiplexed across three loci. Delivered as messenger RNA, ABE8s induce no significant levels of single guide RNA (sgRNA)-independent off-target adenine deamination in genomic DNA and very low levels of adenine deamination in cellular mRNA.
-
Base editors generate allogeneic CAR-T cells with no detectable genomic rearrangements and reduced genotoxicity
ASGCT
Oral presentation at ASGCT
-
In vivo gene editing of the murine Pcsk9 locus using lipid nanoparticle delivered megaTAL mRNA (Poster)
American Society of Gene and Cell Therapy
-
Gene Editing of TRAC Locus Utilizing megaTAL Nucleases Increases Expression of Transgenic TCRs Delivered via Lentiviral Vector-Mediated Gene Transfer (Poster)
American Society of Hematology
-
Unbiased off-target ID for megaTAL nucleases (Poster)
Advances in Genome Biology and Technology
-
Design of multi-cistronic, self-replicating RNA replicons with enhanced expression profiles (Poster)
Novartis Vaccines Science Day
-
Sequential Targeted Delivery of Paclitaxel and Camptothecin Using a Cross-Linked “Nanosponge” Network for Lung Cancer Chemotherapy
Molecular Pharmaceutics
The applicability of a HVGGSSV peptide targeted “nanosponge” drug delivery system for sequential administration of a microtubule inhibitor (paclitaxel) and topoisomerase I inhibitor (camptothecin) was investigated in a lung cancer model. Schedule-dependent combination treatment with nanoparticle paclitaxel (NP PTX) and camptothecin (NP CPT) was studied in vitro using flow cytometry and confocal imaging to analyze changes in cell cycle, microtubule morphology, apoptosis, and cell proliferation…
The applicability of a HVGGSSV peptide targeted “nanosponge” drug delivery system for sequential administration of a microtubule inhibitor (paclitaxel) and topoisomerase I inhibitor (camptothecin) was investigated in a lung cancer model. Schedule-dependent combination treatment with nanoparticle paclitaxel (NP PTX) and camptothecin (NP CPT) was studied in vitro using flow cytometry and confocal imaging to analyze changes in cell cycle, microtubule morphology, apoptosis, and cell proliferation. Results showed significant G2/M phase cell cycle arrest, changes in microtubule dynamics that produced increased apoptotic cell death and decreased proliferation with initial exposure to NP PTX, followed by NP CPT in lung cancer cells. In vivo molecular imaging and TEM studies validated HVGGSSV-NP tumor binding at 24 h and confirmed the presence of Nanogold labeled HVGGSSV-NPs in tumor microvascular endothelial cells. Therapeutic efficacy studies conducted with sequential HVGGSSV targeted NP PTX and NP CPT showed 2-fold greater tumor growth delay in combination versus monotherapy treated groups, and 4-fold greater delay compared to untargeted and systemic drug controls. Analytical HPLC/MS methods were used to quantify drug content in tumor tissues at various time points, with significant paclitaxel and camptothecin levels in tumors 2 days postinjection and continued presence of both drugs up to 23 days postinjection. The efficacy of the NP delivery system in sequential treatments was corroborated in both in vitro and in vivo lung cancer models showing increased G2/M phase arrest and microtubule disruption, resulting in enhanced apoptotic cell death, decreased cell proliferation and vascular density.
Patents
Courses
-
Biomedical Information
-
-
Biostatistics
-
-
Cave Ecology
-
-
Comprehensive Immunology
-
-
Ecology
-
-
Evolutionary Genetics
-
-
Fundamentals of Biotechnology
-
-
Immunology
-
-
Introduction to Biochemistry and Molecular Biology
-
-
Invertebrate Biology
-
-
Medical Biochemistry
-
-
Medical Physiology
-
-
Microbiology
-
-
Organic Chemistry I
-
-
Organic Chemistry II
-
-
Pharmacology
-
-
The Biology of Viruses
-
Languages
-
English
Native or bilingual proficiency
Recommendations received
1 person has recommended Aaron
Join now to viewMore activity by Aaron
-
XGEN Venture, a newly formed Venture Capital firm announces its first fund, XGEN Venture Life Science Fund, with €160M in subscriptions. With this…
XGEN Venture, a newly formed Venture Capital firm announces its first fund, XGEN Venture Life Science Fund, with €160M in subscriptions. With this…
Liked by Aaron Edwards
-
Last week marked the end of Creative Destruction Lab's 2023/24 cohort year, and it was wrapped up in style! Nearly 1000 attendees, including…
Last week marked the end of Creative Destruction Lab's 2023/24 cohort year, and it was wrapped up in style! Nearly 1000 attendees, including…
Liked by Aaron Edwards
-
Spot on. Machine learning for biology (and medicinal chemistry), as a field, must measure the right things.
Spot on. Machine learning for biology (and medicinal chemistry), as a field, must measure the right things.
Liked by Aaron Edwards
-
Founders, beware of the so-called "master investor lists" circulating on LinkedIn. Falling for these shortcuts is a rookie mistake. Cold emailing…
Founders, beware of the so-called "master investor lists" circulating on LinkedIn. Falling for these shortcuts is a rookie mistake. Cold emailing…
Liked by Aaron Edwards
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Aaron Edwards in United States
-
Aaron Edwards
Talent Sourcer | Executive Search | SaaS | DEI
-
Aaron Edwards
-
Aaron Edwards
Director of Food and Beverage
-
Aaron Edwards
Director of Digital Customer Acquisition at Family Help and Wellness
-
Aaron Edwards
writer, story editor, and director
410 others named Aaron Edwards in United States are on LinkedIn
See others named Aaron Edwards